318 results on '"KISH, JONATHAN"'
Search Results
102. Acute myeloid leukemia in the elderly: what constitutes treatment value?
103. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
104. Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer.
105. Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
106. Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) targeted therapy (TT) or immuno-oncology (I-O) agents at US-based community oncology practices.
107. Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D+T) v ipilimumab/nivolumab (I+N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.
108. Real-world evidence (RWE) to show improved time to progression among resected pancreatic cancer (RPC) patients receiving adjuvant chemotherapy (adjch).
109. Opportunities for improving outcomes in pancreatic cancer patients: Characterizing the unresected “resectable” population.
110. HARMONIC ANALYSIS ON THE POSITIVE RATIONALS. DETERMINATION OF THE GROUP GENERATED BY THE RATIOS
111. Intravaginal practices are associated with greater odds of high-risk HPV infection in Haitian women
112. Prioritizing US Cervical Cancer Prevention With Results From a Geospatial Model
113. Acute myeloid leukemia in the elderly: what constitutes treatment value?
114. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model
115. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
116. Evaluation of real-world electronic medical record (EMR) treatment outcome data compared to clinical trial data for an advanced breast cancer treatment.
117. Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs
118. Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer
119. Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.
120. Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.
121. Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy
122. Surgical, radiological, and chemotherapy treatment patterns for non-metastatic and metastatic gastric cancer.
123. Adherence to chemotherapy guidelines for non-metastatic (NM) and metastatic (M) colorectal cancer (CRC).
124. Adherence to guideline-recommended chemotherapy in the treatment of gastric cancer.
125. Dry Dual Clutch Transmission (DCT) Thermal Model
126. Opioid use among prostate cancer patients with bone metastases.
127. Racial and Ethnic Disparities in Cancer Survival by Neighborhood Socioeconomic Status in Surveillance, Epidemiology, and End Results (SEER) Registries
128. Evaluation of national treatment trends in ovarian cancer.
129. Intravaginal practices are associated with greater odds of high-risk HPV infection in Haitian women.
130. Disconnect between earlier presentation patterns and application of curative treatments in HCC.
131. Coping With Vicarious Trauma in the Aftermath of a Natural Disaster
132. Ethnicity predicts metabolic syndrome after liver transplant
133. Impacts of the 2010 Haitian Earthquake in the Diaspora: Findings from Little Haiti, Miami, FL
134. Mo1918 Sirolimus use is Associated With Increased Risk for Cardiovascular Events Following Liver Transplantation
135. Burden of Human Papillomavirus among Haitian Immigrants in Miami, Florida: Community-Based Participatory Research in Action
136. Daily measures of microbes and human health at a non-point source marine beach
137. Shedding of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus from adult and pediatric bathers in marine waters
138. Evaluation of Conventional and Alternative Monitoring Methods for a Recreational Marine Beach with Nonpoint Source of Fecal Contamination
139. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
140. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States.
141. Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients
142. The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients
143. Payer marketing: What strategies should marketers use to position brands for success?
144. Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.
145. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
146. Impacts of the 2010 Haitian Earthquake in the Diaspora: Findings from Little Haiti, Miami, FL.
147. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
148. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
149. Human-Associated Methicillin-Resistant Staphylococcus aureus from a Subtropical Recreational Marine Beach.
150. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.